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To the Editor: 
Stevens-Johnson syndrome (SJS) is a rare life-threatening condition attributed almost 
exclusively to drug exposure (1). The main etiologic factor for SJS is treatment with drugs, 
primarily sulfonamides and anticonvulsants, followed by penicillins and non-steroidal anti-
inflammatory drugs (1). Among penicillins, amoxicillin/clavulanic acid (AMX/CLV), despite 
generally being a well-tolerated antimicrobial, has been reported as a risk factor for SJS in 
adults and children in several publications (2, 3). The pathomechanisms of SJS are not fully 
understood, but immunologic mechanisms, reactive drug metabolites, and/or interactions 
between these two have been described in several reviews (4, 5). In this paper, two children 
with SJS due to AMX/CLV treatment were investigated using in vitro testing by studying the 
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expansion of T lymphocytes. The first case (patient #1) is a child treated with AMX/CLV 
during EBV infection, and the second case (patient #2) is a child treated with AMX/CLV 
where other possible diseases were ruled out. 
 
Patient #1 is a Caucasian boy who had already used oral AMX/CLV to treat common upper 
airway infectious diseases. At three years of age, he was treated with oral AMX/CLV syrup 
for an acute febrile pharyngitis (39.8°C) and lymphadenopathy that was later diagnosed as 
EBV infection by serological tests. On the third day, he was evaluated at the emergency 
department of Anna Meyer Children Hospital, where he appeared in poor general condition 
with fever (38.5°C), malaise, generalized maculopapular exanthema (MPE) with purpuric 
lesions covering the entire body surface plus both plantar and palmar regions, redness of the 
eyes, oral erosions of the lips, throat hyperemia, and cervical lymphadenopathy. According to 
these clinical symptoms, he was diagnosed as being affected by SJS due to the treatment with 
AMX/CLV during EBV infection. The drug was stopped and he received supportive 
therapies, including a short course of corticosteroids, fluid replacement with electrolyte 
solution and analgesic therapy, and recovered within 10 days. Six months later, he was 
referred to the Allergy Unit of Anna Meyer children’s hospital for an allergologic work-up.  
According to the European Network for Drug Allergy (ENDA) diagnostic algorithm for in 
vivo allergologic evaluation of non-immediate reaction to β-lactams, patch tests and skin 
intradermal tests (ID) with AMX/CLV were consecutively performed (6). Patch tests at 5 and 
20% in petrolatum were tested, with negative readings 15 minutes after removal of the strips 
and 24-48 hours later (7). Intradermal testing with AMX/CLV at 2-20 mg/ml concentrations 
was also negative (including delayed readings at 24, 48 and 72 hours). Positive and negative 
controls for SPT and ID were obtained using histamine (ALK-Abellò, Milan, Italy: 10 and 1 
mg/mL) and normal saline. A positive Patch test was defined as when an infiltrate was 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
detected. Skin testing was considered positive either when the ID was greater than 3 mm 
from the initial wheal or when an increase in the diameter of the initial wheal was associated 
with a flare, alongside a negative saline control result, within 15 minutes and at 24, 48, and 
72 hours (6, 7). 
 
Despite the negative results of in vivo testing, we advised his parents to absolutely avoid 
AMX/CLV. One year and a half later, he came to our Allergy Unit for a follow-up visit. At 
that time, we were able to perform the Lymphocyte transformation tests (LTT) and the 
induction of hapten-specific short-term T-cell lines (TCLs) (8). 
 
PBMC were isolated using a Lymphoprep (Sentinel Diagnostic, Milan, Italy) density gradient 
followed by two washings with PBS at pH 7.2. Groups of 2x10
5
 cells were cultured in 
triplicate in round-bottomed 96-well plates in complete medium plus 5% heat-inactivated 
autologous serum in a final volume of 0.2 ml for 5 days in the presence of 4 increasing doses 
of each β-lactam antibiotic (PEN 2.5-0.5-0.1-0.02 mg/ml, AMP 2.5-0.5-0.1-0.02 mg/ml, 
AMX 1-0.5-0.1-0.02 mg/ml, AMX/CLV 0.5-0.1-0.02-0.004 mg/ml) or medium alone as a 
negative control at 37°C in a 5% CO2 humidified atmosphere. As positive controls, 2500 
UI/ml recall antigen streptokinase (SK) and 1% vol/vol polyclonal activator 
phytohemagglutinin (PHA) were used. After 16 h pulsing with 0.5 μCi 3HTdR per well 
(PerkinElmer, Waltham, MA, USA), cultures were harvested, and radionuclide uptake was 
measured by scintillation counting. The stimulation index (SI) was calculated as the ratio 
between the radioactivity from stimulated cultures and that from unstimulated cultures.6 An 
SI ≥ 3 was considered to be positive. TCLs were generated as previously described 6 by 
culturing 1x106 PBMCs in the presence of single drugs (PEN 0.5 mg/ml, AMP 0.5 mg/ml, 
AMX 0.5 mg/ml and AMX/CLV  0.1 mg/ml) for 6 days. Activated T cells were then 
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expanded for a further 8 days by the addition of rIL-2 (25 U/ml) every three days. At the end 
of the culture period, T cell blasts were recovered, washed, counted, adjusted to 1x106/ml and 
assessed for specificity by thymidine incorporation in the presence of the respective drug 
(PEN, AMP and AMX 0.5 mg/ml, AMX/CLV 0.1 mg/ml) and autologous irradiated PBMC 
(1:1 ratio) for 3 days. An SI ≥ 3 was considered to be positive.   
 
LTT was negative for both AMX and AMX/CLV, whereas Penicillin (PEN)-specific T-cell 
lines could be obtained (data not shown). Six months later (2 years since the SJS episode), 
LTT, induction of hapten-specific TCLs and intracellular fluorescent labeling with 
carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) to track proliferating T-cells 
were performed (8). First, 10x106/ml PBMCs were labeled for 4 minutes with 5 μM CFDA-
SE (Invitrogen, Carlsbad, CA, USA) in PBS; then the cells were extensively washed, and 
2x105 labeled cells were cultured in quadruplicate in round-bottomed 96-well plates in the 
presence of 3 scalar doses of each β-lactam (PEN 2.5-0.25-0.025 mg/ml, AMP 2.5-0.25-
0.025 mg/ml, AMX 1-0.25-0.025 mg/ml, AMX/CLV 0.25-0.025-0.0025 mg/ml) at 37°. 
Medium was used as a negative control. SK and PHA were used as positive controls, as 
described above. On day 7, total rabbit IgG was added to each tube to saturate non-specific 
binding sites, and the cultures were then incubated with specific (PB anti-CD3, APC-Cy7 
anti-CD8, APC anti-CD4) or isotype control mAbs (Becton Dickinson) for 20 minutes at 
4°C. Cells were analyzed using a FACSCalibur cytofluorimeter (Becton Dickinson) and 
gated as CD3+CD4+, acquiring a total of 104 events for each sample. The results are 
expressed as the stimulation index, calculated as the ratio of the geometric Mean 
Fluorescence Intensity of proliferating cells between stimulated and unstimulated cultures. 
LTT remained negative and TCL induction confirmed the previous results (Fig. 1A). –
CFDA-SE - assay towards PEN, Ampicillin (AMP), AMX, and AMX/CLV was positive on 
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day 7 of incubation, with proliferation of specific T-cells of the CD4+ (Fig. 1B) and CD8+ 
(data not shown) phenotype. Clinical history and positive in vitro tests, together with positive 
serologic testing for EBV, indicated that our patient had experienced SJS due to AMX/CLV 
and EBV infection. 
 
Patient #2 is a 16 year old Moroccan boy admitted to Anna Meyer Children hospital because 
of SJS. 
Two days after finishing a six-day treatment with oral AMX/CLV, he developed bullous 
lesions at the upper arms, hard palate, gingivae and lips without fever. Itchy scabs and flaccid 
blisters filled with serous liquid were located on genital mucosae (Fig. 2). Multiple bilateral 
lymphadenopathies (< 1 cm diameter) were detected in the neck. Laboratory investigation 
showed the following: an increased white blood cell count (13.5 x109/L; normal range 4-10 
x109/L) without eosinophilia; increased erythrocyte sedimentation rate (ESR) (53 mg/dL), 
CRP (6.09 mg/dL) and fibrinogen (683 mg/dL, normal range: 200-400 mg/dl); elevated liver 
aspartate aminotransferase (98 IU/L, normal range 3-40 IU/L); and normal prothrombin time 
and renal function tests. All infectious screening tests, including viruses (HSV 1 and 2, HCV, 
HIV, Adenovirus, Enterovirus, EBV, CMV), bacteria (Streptococcus pyogenes, Salmonella 
typhi and paratyphi, Brucella, Staphylococcus aureus, Syphilis) and other pathogens 
(including Strongyloides spp., Toxocara canis, Mycobacterium tuberculosis, Fusobacterium 
necrophorum and Mycoplasma pneumonia) were negative. Blood cultures were also negative. 
Therefore, AMX/CLV-induced SJS was suspected. Intravenous corticosteroids and skin care 
were started with a favorable outcome. In one week, lesions had progressively improved, and 
the patient was discharged with advice to avoid AMX/CLV. Six months later, he was referred 
to the Allergy Unit of Anna Meyer Children’s Hospital where he was investigated for 
AMX/CLV hypersensitivity. In vivo tests were performed according to the European 
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Network for Drug Allergy (6,7) recommendations in the following sequence: patch tests with 
AMX/CLV at 5 and 20% in petrolatum with readings at 24-48 hours and intradermal (ID) 
testing with 1/100 and 1/10 dilutions of the full-strength (200 mg/mL) AMX/CLV 
concentration at 20- to 30-minute intervals. ID tests were also read after 24, 48, and 72 hours 
for delayed T-cell-mediated reactions. In vivo test results were all negative. In vitro studies 
including LTT, induction of hapten-specific short-term TCLs and CFDA-SE assay were 
subsequently performed. The LTT results were negative (data not shown), AMP-specific 
TCLs proliferated against PEN (Fig. 1A) and, of note, – CFDA-SE - assay results were 
positive for AMX in CD4+ cells exclusively (Fig. 1B) (8).  
 
SJS frequently requires hospitalization in childhood and is due to a Type IV hypersensitivity 
reaction towards drugs. The role of pathogens in SJS is still undefined. The clinical diagnosis 
of severe, delayed drug-hypersensitivity reactions is challenging, and the diagnostic value of 
current allergologic tests is not well defined. In our patients, according to ENDA (6), patch 
tests were used as part of the first line investigation. These are reported as safer than 
intradermal (ID) tests that can be avoided in cases of positive results. Patch tests are, 
however, less sensitive (albeit more specific) than delayed-reading ID tests (7), especially 
when performed alone. Sensitivity is reported as ranging between 10.8 and 37.5%, depending 
on the publication, and this variability depends on the vehicle used, the type of eruption and 
the involved drug. It has been reported that the negative predictive value of drug skin testing 
is approximately 90% (9). Our results stand in contrast with the literature (10), as in vivo 
testing was of no clinical utility for the diagnosis of SJS to AMX/CLV. Provocation tests, the 
gold standard of a negative allergologic work-up, are contraindicated in SJS/TEN because re-
exposure can elicit a new episode with increased severity (6). However, there are currently no 
reliable laboratory tests to determine the offending drug in these cases. In this paper, we show 
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that the extension of the in vitro work-up to less conventional tests was extraordinarily useful 
for identifying the etiology of the severe reaction. AMX/CLV was the suspected drug for SJS 
in both patients, but the lymphocyte transformation test was negative even though all β-
lactams were screened. It has been reported that the range of sensitivity for LTT is highly 
variable, but in particular, it is less than 30% in SJS/TEN (11). In our hands, the induction of 
short-term T cell lines (TCLs), and particularly cytofluorometric assessment of lymphocyte 
proliferation by CFDA-SE assay, resulted in the demonstration of circulating β-lactam-
specific T lymphocyte (Fig. 1) with a specific response to the combination of AMX and CLV 
in patient #- 1. Unfortunately, the role of CLV in the sensitization cannot be exploited as 
CLV was not individually tested. Although skin biopsies were not performed, clinical 
manifestations were highly suggestive for SJS (Fig. 2) The role played by concurrent 
infections was unclear. In patient #1, cellular-mediated hypersensitivity towards AMX/CLV 
persisted two years after the reaction, and we suggest that EBV may have additionally 
contributed to the development of SJS. The hypothesis describing facilitation of drug 
sensitization by EBV is still controversial. However, the hypothesis that medications and 
pathogens such as EBV could contribute to drug reactions remains very popular, particularly 
given the high frequency of skin rashes resulting from aminopenicillin treatment during 
infectious mononucleosis (12). This hypothesis has never been supported by clear evidence in 
SJS/TEN, where a complete screening for infections, in particular for primary EBV infection 
(12), should be performed in all SJS cases without any imputable medication. Our results 
suggest that clinicians should be aware of the risk of AMX/CLV-induced SJS in children and 
that identification of the culprit drug may be aided by in vitro tests. These latter tests may be 
of importance for the growing patient to avoid recurrence, particularly given the concrete risk 
of a fatal outcome.  
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Legend to the Figures 
 
Figure 1 Specificity of hapten-specific T-cell lines and proliferation of CFDA-SE-labeled 
PBMCs towards beta-lactams.  
A: Short term hapten-specific TCLs were generated from PBMCs of patients #1 and #2 in the 
presence of PEN, AMP, AMX or AMX/CLV as described in the text. Specificity was 
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assessed under MHC-restricted conditions against each β-lactam by 3H thymidine 
incorporation. The results are expressed as stimulation index and the dotted line represents 
the cut-off of positivity (SI≥ 3).  
B: CFDA-SE-labeled PBMCs from patients #1 and #2 were cultured in the presence of scalar 
concentrations (dose 1 > dose 2 > dose 3) of PEN, AMP, AMX or AMX/CLV or positive 
controls (SK and PHA) and proliferating CD3+CD4+ cells were analyzed by FACS as 
described. The results are expressed as stimulation index and the dotted line represents the 
cut-off of positivity (SI≥ 3). Representative plots of CD3+CD4+ gated cells for each patient 
are also shown (AMX dose 1). 
 
 
Figure 2 Patient #2 “target” lesions and extensive mucous membrane involvement with 
flaccid blisters affecting the hands. 
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